Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a multicenter Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled
Study to Demonstrate the Efficacy and Safety of tildrakizumab in Subjects with Active
Psoriatic Arthritis I (INSPIRE 1)
Phase:
Phase 3
Details
Lead Sponsor:
Sun Pharma Global FZE Sun Pharmaceutical Industries Limited